MORRIS PLAINS, N.J., March 7, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that Ms. Marcella LoCastro, CPA.CITP, has been appointed to the Company's Board of Directors.
